vs
CHOICEONE FINANCIAL SERVICES INC（COFS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
CHOICEONE FINANCIAL SERVICES INC的季度营收约是REGENXBIO Inc.的1.4倍（$42.9M vs $30.3M），CHOICEONE FINANCIAL SERVICES INC同比增速更快（76.4% vs 43.0%），CHOICEONE FINANCIAL SERVICES INC自由现金流更多（$25.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.0%）
ChoiceOne Financial Services Inc是一家美国区域金融控股公司，通过旗下银行子公司开展业务，主要为密歇根州的个人消费者、小微企业及企业客户提供储蓄账户、贷款、财富管理、保险等多元化个人及商业银行服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
COFS vs RGNX — 直观对比
营收规模更大
COFS
是对方的1.4倍
$30.3M
营收增速更快
COFS
高出33.4%
43.0%
自由现金流更多
COFS
多$78.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
15.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $42.9M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 39.1% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 76.4% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $1.43 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COFSRGNX
| Q4 25 | $42.9M | $30.3M | ||
| Q3 25 | $61.8M | $29.7M | ||
| Q2 25 | $60.4M | $21.4M | ||
| Q1 25 | $44.9M | $89.0M | ||
| Q4 24 | $24.3M | $21.2M | ||
| Q3 24 | $36.6M | $24.2M | ||
| Q2 24 | $34.0M | $22.3M | ||
| Q1 24 | $32.5M | $15.6M |
净利润COFSRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $14.7M | $-61.9M | ||
| Q2 25 | $13.5M | $-70.9M | ||
| Q1 25 | $-13.9M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $7.3M | $-59.6M | ||
| Q2 24 | $6.6M | $-53.0M | ||
| Q1 24 | $5.6M | $-63.3M |
毛利率COFSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率COFSRGNX
| Q4 25 | 39.1% | -190.0% | ||
| Q3 25 | 29.6% | -176.3% | ||
| Q2 25 | 27.6% | -296.3% | ||
| Q1 25 | -39.2% | 13.6% | ||
| Q4 24 | 36.1% | -242.1% | ||
| Q3 24 | 25.4% | -256.6% | ||
| Q2 24 | 24.0% | -251.3% | ||
| Q1 24 | 21.1% | -408.8% |
净利率COFSRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 23.7% | -208.3% | ||
| Q2 25 | 22.4% | -331.8% | ||
| Q1 25 | -31.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 20.1% | -246.3% | ||
| Q2 24 | 19.4% | -237.7% | ||
| Q1 24 | 17.3% | -405.4% |
每股收益（稀释后）COFSRGNX
| Q4 25 | $1.43 | $-1.30 | ||
| Q3 25 | $0.97 | $-1.20 | ||
| Q2 25 | $0.90 | $-1.38 | ||
| Q1 25 | $-1.29 | $0.12 | ||
| Q4 24 | $0.79 | $-0.99 | ||
| Q3 24 | $0.85 | $-1.17 | ||
| Q2 24 | $0.87 | $-1.05 | ||
| Q1 24 | $0.74 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $88.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $465.4M | $102.7M |
| 总资产 | $4.4B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资COFSRGNX
| Q4 25 | $88.0M | $230.1M | ||
| Q3 25 | $99.0M | $274.2M | ||
| Q2 25 | $156.3M | $323.3M | ||
| Q1 25 | $139.4M | $267.9M | ||
| Q4 24 | $96.8M | $234.7M | ||
| Q3 24 | $145.9M | $255.5M | ||
| Q2 24 | $101.0M | $290.4M | ||
| Q1 24 | $150.1M | $338.7M |
股东权益COFSRGNX
| Q4 25 | $465.4M | $102.7M | ||
| Q3 25 | $449.6M | $161.5M | ||
| Q2 25 | $431.8M | $213.7M | ||
| Q1 25 | $427.1M | $274.2M | ||
| Q4 24 | $260.4M | $259.7M | ||
| Q3 24 | $247.7M | $301.4M | ||
| Q2 24 | $214.5M | $348.3M | ||
| Q1 24 | $206.8M | $390.7M |
总资产COFSRGNX
| Q4 25 | $4.4B | $453.0M | ||
| Q3 25 | $4.3B | $525.2M | ||
| Q2 25 | $4.3B | $581.0M | ||
| Q1 25 | $4.3B | $490.9M | ||
| Q4 24 | $2.7B | $466.0M | ||
| Q3 24 | $2.7B | $519.1M | ||
| Q2 24 | $2.7B | $569.4M | ||
| Q1 24 | $2.7B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $25.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 58.7% | -174.0% |
| 资本支出强度资本支出/营收 | 15.4% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $38.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流COFSRGNX
| Q4 25 | $31.8M | $-52.3M | ||
| Q3 25 | $15.3M | $-56.0M | ||
| Q2 25 | $9.0M | $-49.3M | ||
| Q1 25 | $-6.5M | $33.6M | ||
| Q4 24 | $47.1M | $-31.6M | ||
| Q3 24 | $-7.4M | $-40.5M | ||
| Q2 24 | $15.7M | $-45.5M | ||
| Q1 24 | $15.3M | $-55.5M |
自由现金流COFSRGNX
| Q4 25 | $25.2M | $-52.8M | ||
| Q3 25 | $13.7M | $-56.5M | ||
| Q2 25 | $6.9M | $-49.7M | ||
| Q1 25 | $-7.3M | $32.6M | ||
| Q4 24 | $45.4M | $-32.7M | ||
| Q3 24 | $-7.6M | $-40.9M | ||
| Q2 24 | $15.3M | $-46.0M | ||
| Q1 24 | $15.0M | $-56.0M |
自由现金流率COFSRGNX
| Q4 25 | 58.7% | -174.0% | ||
| Q3 25 | 22.1% | -189.9% | ||
| Q2 25 | 11.4% | -232.8% | ||
| Q1 25 | -16.3% | 36.6% | ||
| Q4 24 | 186.4% | -154.2% | ||
| Q3 24 | -20.8% | -168.9% | ||
| Q2 24 | 44.8% | -206.2% | ||
| Q1 24 | 46.2% | -358.5% |
资本支出强度COFSRGNX
| Q4 25 | 15.4% | 1.7% | ||
| Q3 25 | 2.6% | 1.7% | ||
| Q2 25 | 3.4% | 1.8% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 7.0% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 1.4% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率COFSRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.04× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.00× | — | ||
| Q2 24 | 2.39× | — | ||
| Q1 24 | 2.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COFS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
